Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Conditions
Interventions
Control Intervention1: NIL: NIL
Sponsors
Tata Research Administrative Council
Eligibility
Inclusion criteria
Inclusion criteria: Following are the inclusion criteria for enrollment of the study participants. 1-Head-neck cancer patients who are planned to receive Cisplatin-based definitive or adjuvant chemo-radiotherapy 2-Head-neck cancer patients who are able to provide consistent and reliable responses in conventional pure-tone audiometry. 3-Head-neck cancer patients who have not received any known ototoxic cancer treatment before. 4-Head-neck cancer patients without any known cognitive or psychological problems
Exclusion criteria
Exclusion criteria: Following ear-wise exclusion criteria at the time of enrollment will be taken for the study. 1-Ears of Head-neck cancer patients with air Conduction Hearing thresholds >50dBHL at any of the octave-band test frequencies between 0.5 to 8 KHz. 2-Ears of Head-neck cancer patients with Distortion Product Oto-acoustic Emission (DPOAE)Signal to Noise Ratio (SNR) level 3-Ears of Head-neck cancer patients with presence of any Conductive hearing loss at baseline or at end-of-treatment evaluation. 4-Ears of Head-neck cancer patients with a history of previous ear surgery 5-Ears of Head-neck cancer patients with any known pre-treatment hearing loss documented in baseline audiogram.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To establish the criteria of ototoxic hearing loss with highest agreement between interpretation of PTA and OAE findings between 1.5 to 6 kHZTimepoint: It will be analyzed based on the audiological findings within three months of completion of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| To check any significant audiological changes in findings of PTA & DPOAE across all time points. Timepoint: It will be analyzed based on the findings of the evaluation conducted after two cycles of chemotherapy & follow up evaluation conducted within three months of completion chemotherapy.;To check the agreement between interpretation of PTA & DPOAE findings based on the newly set criteria of defining auditory abnormality at all other time points. Timepoint: It will be analyzed based on the findings of the evaluation conducted after two cycles of chemotherapy | — |
Countries
India
Contacts
Public Contactjitesh prasad sahoo
Tata Memorial Hospital
Outcome results
None listed